Our News and Events

Come meet us at an upcoming event.

September 5-6, 2018   BioPharm America
Boston, Massachusetts

September 6, 2018   RESI
Boston, Massachusetts

September 25-26, 2018   CNS Diseases Summit
Boston, Massachusetts

October 3-7, 2018   ID Week
San Francisco, California

October 10-12, 2018   BioNetwork West
Laguna Nigel, California

October 14-17, 2018   LES Annual Meeting
Boston, Massachusetts

October 17-18, 2018   BIO Investor Forum
San Francisco, California

October 24-25, 2018   Life Sciences Summit
New York, New York

October 27-30, 2018   Annual Ophthalmology Meeting (AAO)
Chicago, Illinois

October 29-30, 2018   Life Sciences Future
Philadelphia, Pennsylvania

November 1, 2018   Philly BioBreak
Philadelphia, Pennsylvania

November 3-7, 2018   Society for Neuroscience (SFN)
San Diego, California

November 5, 2018   RESI
New York, New York

November 7-11, 2018   Society for Immunotherapy of Cancer (SITC)
Washington, D.C.

November 11-14, 2018   American Heart Association (AHA)
Chicago, Illinois

November 13-14, 2018   SEBIO Investor Forum
Atlanta, Georgia

December 1-4, 2018   American Society of Hematology (ASH) Annual Meeting
San Diego, California



October 1, 2018   Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors
July 24, 2018   Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
July 12, 2018   Pfenex Receives Milestone From Merck Associated With Clinical Advancement of Investigational 15-valent Pneumococcal Vaccine PCV-15 (V114)
July 12, 2018   Cue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck
May 3, 2018   Moderna and Merck Expand mRNA Cancer Vaccines Collaboration
March 7, 2018   Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)
February 21, 2018   Merck and Viralytics Announce Acquisition Agreement, Expanding Merck’s Leading Immuno-Oncology Pipeline
November 16, 2017   Cue Biopharma Announces Strategic Research Collaboration and License Agreement with Merck
October 10, 2017   KalVista Pharmaceuticals Announces Collaboration with Merck
September 6, 2017   Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology
July 27, 2017   AstraZeneca and Merck Establish Strategic Oncology Collaboration
June 20, 2017   SerImmune Inc. Announces Discovery and Development Collaboration with Merck
May 25, 2017   Merck Enters Exclusive Worldwide License Agreement with Teijin Pharma for Investigational Antibody Candidate Targeting Tau
March 17, 2017   New partnership to accelerate development of treatments for neurological diseases
March 1, 2017   GRAIL Closes Over $900 Million Initial Investment in Series B Financing to Develop Blood Tests to Detect Cancer Early
January 5, 2017   Cerveau Technologies, Inc. Signs License Agreement with Merck for Novel Investigational Tau Imaging Agent
November 14, 2016   OpGen Collaborates With Merck to Develop Novel Rapid Diagnostics and Informatics Tools to Combat Antibiotic Resistance
August 24, 2016   Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications
July 25, 2016   Enigma Biomedical Group Inc Signs Research Agreement with Biogen and Merck for Novel Tau Imaging Agent
June 29, 2016   Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer
June 9, 2016   Merck to Acquire Afferent Pharmaceuticals
June 7, 2016   Innovative Targeting Solutions Announces Research Collaboration with Merck
March 21, 2016   Blavatnik Biomedical Accelerator at Harvard University Announces License and Collaboration Agreement with Merck to Develop Novel Cancer Therapeutics
February 29, 2016   NanoString Technologies and Merck Expand Collaboration to Develop and Commercialize Novel Diagnostic Test to Predict Response to KEYTRUDA® (pembrolizumab)
February 24, 2016   AureoGen Announces Licensing Agreement with Merck
January 11, 2016   Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program
January 6, 2016   Quartet Medicine Announces Strategic Partnership with Merck
December 4, 2015   Amgen and Merck Announce Cancer Immunotherapy Collaboration for Patients with Non-Hodgkin Lymphoma
November 19, 2015   Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
October 22, 2015   MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA® (pembrolizumab) for Advanced Gastric Cancer
October 1, 2015   Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
September 28, 2015   Syndax and Merck Announce First Patients Dosed in Phase 1b/2 Clinical Trial of Entinostat and KEYTRUDA®
September 8, 2015   Merck and Samsung Bioepis Announce Approval of BRENZYS™ (Etanercept), a Biosimilar of Enbrel, in Korea
August 31, 2015   Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus
August 13, 2015   Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors
August 10, 2015   Immune Design and Merck to Collaborate on Combination Trials of Two Immune Design Immunotherapies with Merck’s KEYTRUDA® for Non-Hodgkin’s Lymphoma and Melanoma
August 3, 2015   Codexis Announces CodeEvolver Technology Transfer and License Agreement With Merck
July 28, 2015   Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics
July 7, 2015   Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program
June 1, 2015   Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies
May 30, 2015   TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA® (pembrolizumab)
May 29, 2105   Amgen and Merck Announce Expansion of Collaboration to Support Studies of Talimogene Laherparepvec in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head and Neck Cancer
May 28, 2015   Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab)
May 7, 2015   Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen
April 20, 2015   TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors
April 7, 2015   Arvinas Announces Strategic R&D Collaboration with Merck to Study Novel Protein Degradation Technology
March 31, 2015   Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma
March 25, 2015   Lycera Announces Milestone in Merck Collaboration
March 4, 2015   Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer
February 23, 2015   NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics
January 13, 2015   Moderna Announces License and Collaboration Agreement with Merck to Develop Messenger RNA-based Antiviral Vaccines and Passive Immunity Therapies
January 13, 2015   Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer
December 18, 2014   Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers
December 8, 2014   New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma
December 8, 2014   Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash
November 24, 2014   Merck and NewLink Genetics Enter into Licensing and Collaboration Agreement for Investigational Ebola Vaccine
November 6, 2014   BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology
September 17, 2014   Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab
August 26, 2014   Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen
August 25, 2014   Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer
June 9, 2014   Merck to Acquire Idenix
April 28, 2014   Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-based Cancer Immunotherapies
March 26, 2014   Merck Licenses Nanobio Technology
February 10, 2014   Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes
February 5, 2014   Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475
January 13, 2014   Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma